Overview
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.
Basic Stats
The share price of Fulcrum Therapeutics, Inc. as of September 4, 2025 is $6.88 / share. This is an increase of 3.46% from the prior week. The market cap (or net worth) of Fulcrum Therapeutics, Inc. as of September 4, 2025 is $372.15 MM.
The Factor Analysis chart (below right) shows a view of Fulcrum Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 372.15 MM |
| EV | 329.56 MM |
| Shares Out. | 54.09 MM |
| Earnings Date | |
| EPS (TTM) | -1.35 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.93 |
| Short Shares Avail. | 0.95 MM |
| Short Interest | 5.82 MM |
| Short Float | 24.50 % |
| Days to Cover | 23.94 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | -16.61 % |
| Volatility (1 yr) | 1.03 |
| Beta | 0.79 |
| Sharpe Ratio (1 yr) | -0.20 |
| Sortino Ratio (1 yr) | -0.30 |
| PE Ratio | -5.08 |
| Price/Book | 1.74 |
| Price/TBV | 1.74 |
| Book/Market | 0.58 |
| EBIT/EV | -0.22 |
| EBIT(3yr avg)/EV | -0.19 |
| ROA | -0.25 |
| ROE | -0.27 |
| ROIC | -0.33 |
| CROIC | -0.20 |
| OCROIC | -0.29 |
| Implied Volatility | 88.48 % |
| Put/Call OI Ratio | 0.08 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Fulcrum Therapeutics, Inc. is $11.29. The forecasts range from a low of $5.05 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Fulcrum Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-19 | Goldman Sachs | Buy | Maintains | |
| 2023-01-23 | Piper Sandler | Overweight | Maintains | |
| 2022-11-15 | Goldman Sachs | Buy | Initiate | |
| 2022-11-14 | Morgan Stanley | Overweight | Maintains | |
| 2022-11-09 | Credit Suisse | Outperform | Maintains | |
| 2022-06-13 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-05-17 | Morgan Stanley | Overweight | Maintains | |
| 2022-04-12 | Morgan Stanley | Overweight | Maintains | |
| 2022-03-25 | Credit Suisse | Outperform | Maintains | |
| 2022-03-08 | Oppenheimer | Outperform | Initiate | |
| 2021-08-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-08-13 | SVB Leerink | Outperform | Maintains | |
| 2021-08-11 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2021-08-11 | Credit Suisse | Outperform | Maintains | |
| 2021-03-22 | Credit Suisse | Outperform | Initiate | |
| 2020-10-16 | Piper Sandler | Overweight | Initiate | |
| 2020-08-12 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2020-08-12 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-08-12 | B of A Securities | Neutral | Underperform | Downgrade |
| 2021-03-08 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-03-02 | Stifel | Buy | Initiate | |
| 2020-11-10 | SVB Leerink | Outperform | Maintains | |
| 2020-06-19 | B of A Securities | Buy | Neutral | Downgrade |
| 2020-06-17 | BTIG | Buy | Initiate | |
| 2020-03-06 | H.C. Wainwright | Buy | Reiterate | |
| 2020-01-23 | B of A Securities | Buy | Maintains | |
| 2019-10-03 | H.C. Wainwright | Buy | Initiate | |
| 2019-08-12 | Morgan Stanley | Overweight | Initiate | |
| 2019-08-12 | Bank of America | Buy | Initiate | |
| 2023-01-24 | Morgan Stanley | Overweight | Maintains | |
| 2023-02-28 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2023-02-27 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-02-27 | Credit Suisse | Outperform | Maintains | |
| 2023-02-27 | Oppenheimer | Outperform | Maintains | |
| 2023-02-28 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-03-13 | Goldman Sachs | Buy | Maintains | |
| 2023-03-10 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2023-03-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2023-03-10 | Credit Suisse | Outperform | Neutral | Downgrade |
| 2023-05-04 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2023-05-05 | Goldman Sachs | Neutral | Maintains | |
| 2023-05-16 | Oppenheimer | Outperform | Outperform | Maintains |
| 2023-05-16 | HC Wainwright & Co. | Neutral | Neutral | Maintains |
| 2023-08-23 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
| 2023-08-04 | HC Wainwright & Co. | Neutral | Neutral | Reiterate |
| 2023-08-22 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-08-22 | Stifel | Hold | Buy | Upgrade |
| 2024-01-25 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2023-09-25 | Goldman Sachs | Neutral | Initiate | |
| 2024-05-20 | Cantor Fitzgerald | Overweight | Initiate | |
| 2024-05-13 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2024-05-14 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2024-05-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-14 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-02-28 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-02-28 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-03-13 | RBC Capital | Outperform | Initiate | |
| 2024-01-26 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-07-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-09-13 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2024-11-14 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2024-11-14 | HC Wainwright & Co. | Neutral | Neutral | Reiterate |
| 2024-09-13 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2024-09-12 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2024-09-12 | Stifel | Buy | Hold | Downgrade |
| 2024-09-12 | B of A Securities | Neutral | Underperform | Downgrade |
| 2024-09-12 | Leerink Partners | Outperform | Market Perform | Downgrade |
| 2024-08-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-09 | B of A Securities | Underperform | Neutral | Upgrade |
| 2025-05-29 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-02-26 | HC Wainwright & Co. | Neutral | Neutral | Reiterate |
| 2025-05-15 | Cantor Fitzgerald | Neutral | Overweight | Upgrade |
| 2025-07-30 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-23 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2025-07-29 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
